Oncology & Cancer

USPSTF advises meds to reduce risk for primary breast cancer

The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians offer risk-reducing medications to women at increased risk for breast cancer and at low risk for adverse medication effects. These recommendations ...

Oncology & Cancer

Ibrance approval expanded to include men with breast cancer

(HealthDay)—U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic ...

Oncology & Cancer

USPSTF recommends risk-reducing meds for breast cancer

(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends risk-reducing medications for women at high risk for breast cancer who are at low risk for adverse events, but medications are not recommended for ...

page 1 from 11